Valuation: Alkermes plc

Market Cap 7.61B 6.81B 6.27B 5.68B 10.61B 722B 10.81B 74.73B 30B 380B 28.55B 27.94B 1,198B P/E 2026 *
-85.9x
P/E 2027 * 74.8x
Enterprise Value 8.53B 7.64B 7.03B 6.37B 11.91B 810B 12.13B 83.84B 33.66B 426B 32.03B 31.35B 1,344B EV / Sales 2026 *
4.68x
EV / Sales 2027 * 4.26x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.07%
1 week+3.92%
Current month+11.90%
1 month+11.90%
3 months-9.37%
6 months+34.50%
Current year+62.04%
1 week 43.45
Extreme 43.45
46.38
1 month 38.98
Extreme 38.98
46.38
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.06
Extreme 22.06
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 53 01/08/2026
Director/Board Member 74 26/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Exercice

Chief Financial Officer

22,397 0.0134%
7/10/26 Free

Director

25,237 0.0150%
2/10/26 Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+3.92%+47.11%+86.51% 7.61B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.55%+5.70%+46.64%+83.48% 426.95B
Weighted average by Cap. +1.19%+6.59%+50.87%+98.29%

Financials

2026 *2027 *
Net sales 1.82B 1.63B 1.5B 1.36B 2.54B 173B 2.59B 17.92B 7.19B 91.08B 6.84B 6.7B 287B 1.94B 1.74B 1.6B 1.45B 2.71B 185B 2.76B 19.1B 7.67B 97.09B 7.29B 7.14B 306B
Net income -92.03M -82.42M -75.81M -68.69M -128M -8.74B -131M -904M -363M -4.6B -345M -338M -14.5B 105M 94.34M 86.78M 78.63M 147M 10B 150M 1.03B 415M 5.26B 395M 387M 16.59B
Net Debt 928M 831M 764M 693M 1.29B 88.11B 1.32B 9.12B 3.66B 46.35B 3.48B 3.41B 146B 670M 600M 552M 500M 935M 63.61B 952M 6.58B 2.64B 33.46B 2.51B 2.46B 106B
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
30/10/26 USD 45.34 -0.07% 1,113,062
29/10/26 USD 45.37 +0.27% 1,427,247
28/10/26 USD 45.25 +2.10% 1,439,723
27/10/26 USD 44.32 -0.27% 1,322,009
26/10/26 USD 44.44 +1.86% 1,176,641
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.34USD
Average target price
56.21USD
Spread / Average Target
+23.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alkermes plc
  1. Stock Market
  2. Stocks
  3. ALKS Stock